CALLA trial: immunotherapy in locally advanced cervical cancer

Bradley J Monk and colleagues reported the results of a randomised controlled trial assessing the benefits of the use of durvalumab, a PD-L1 antibody, with and after concurrent chemoradiotherapy for locally advanced cervical cancer. 1 Monk BJ Toita T Wu X et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24: 1334-1348 Summary Full Text Full Text PDF PubMed Scopus (16) Google Scholar Results from the CALLA study have been highly awaited by gynecological oncologists worldwide. We have analysed the results with keen interest and would like to congratulate the authors for their hard work in this landmark trial. In the intent-to-treat population, the progression-free survival was not significantly different between the durvalumab plus concurrent chemoradiotherapy group and the concurrent chemoradiotherapy group (hazard ratio [HR] 0·84; 95% CI 0·65–1·08; p=0·17). In the subgroup analysis, the progression-free survival benefit in the durvalumab group was observed at PD-L1 tumour area positivity of 20% or greater. This important finding is worthy of further exploration. CALLA trial: immunotherapy in locally advanced cervical cancerWe have read with deep interest the findings from the CALLA trial—a randomised, double blind, phase 3 study that enrolled 770 patients diagnosed with locally advanced cervical cancer. The participants received standard-of-care chemoradiotherapy along with either a fixed dose of 1500 mg durvalumab or a placebo administered every 4 weeks for 24 cycles, or until disease progression.1 Full-Text PDF CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' replyThe CALLA trial was designed to determine the efficacy and safety of the anti-PD-L1 antibody, durvalumab, with and after standard-of-care concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in women with locally advanced cervical cancer.1 Progression-free survival was not substantially improved in a biomarker unselected, all-comers population (hazard ratio [HR] 0·84; 95% CI 0·65–1·08; p=0·17), with no new safety signals identified. Full-Text PDF